To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Lymecycline is a tetracycline broad-spectrum antibiotic marketed by the pharmeceutical company Galderma. It is approximately 5000 times more soluble than tetracycline base and is unique amongst tetracyclines in that it is absorbed by the "active transport" process across the intestinal wall, making use of the same fast and efficient mechanism by which carbohydrates are absorbed.
The greater absorption of Lymecycline allows for lower dosages to be used; the standard dose of 408 mg is equivalent to 300 mg tetracycline base, and in its action to 500 mg tetracycline hydrochloride. Lymecycline, unlike tetracycline hydrochloride, is soluble at all physiological pH values.
Additional recommended knowledge
Lymecycline was released onto the pharmaceutical market in 1963.
Lymecycline, like other Tetracyclines, is used to treat a range of infections (see Tetracycline antibiotics group). Its better absorption profile makes it preferable to tetracycline for moderately severe acne and typically prescribed for 8 weeks at a time, but alternatives should be sought if no improvement occurs by 3 months.
The standard dose is 408mg (one capsule) twelve hourly by mouth. In particularly severe infections this dose may be increased to 1.224-1.632mg (three or four capsules) daily.
The 408mg once daily dosage for acne aids good drug compliance.
Capsules containing 408mg of Lymecycline (brand name Tetralysal 300).
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Lymecycline". A list of authors is available in Wikipedia.|